Last updated: 19 April 2022 at 4:28pm EST

Eric d'Esparbes Net Worth




The estimated Net Worth of Eric D Esparbes is at least $1.46 Million dollars as of 20 May 2018. Mr Esparbes owns over 5,808 units of Progenity stock worth over $328,311 and over the last 9 years he sold PROG stock worth over $526,562. In addition, he makes $602,670 as Chief Financial Officer at Progenity.

Mr Esparbes PROG stock SEC Form 4 insiders trading

Mr has made over 9 trades of the Progenity stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 5,808 units of PROG stock worth $83,635 on 20 May 2018.

The largest trade he's ever made was selling 15,285 units of Progenity stock on 20 November 2017 worth over $202,985. On average, Mr trades about 1,636 units every 27 days since 2016. As of 20 May 2018 he still owns at least 373,081 units of Progenity stock.

You can see the complete history of Mr Esparbes stock trades at the bottom of the page.





Mr. Eric d'Esparbes biography

Eric d'Esparbes is the Chief Financial Officer at Progenity.

What is the salary of Mr Esparbes?

As the Chief Financial Officer of Progenity, the total compensation of Mr Esparbes at Progenity is $602,670. There are no executives at Progenity getting paid more.



How old is Mr Esparbes?

Mr Esparbes is 53, he's been the Chief Financial Officer of Progenity since . There are 4 older and 3 younger executives at Progenity. The oldest executive at Progenity, Inc. is George Gianakopoulos, 59, who is the Sr. VP of Sales.

What's Mr Esparbes's mailing address?

Eric's mailing address filed with the SEC is C/O PROGENITY, INC., 4330 LA JOLLA VILLAGE DRIVE, SUITE 300, SAN DIEGO, CA, 92122.

Insiders trading at Progenity

Over the last 4 years, insiders at Progenity have traded over $0 worth of Progenity stock and bought 34,001,547 units worth $176,045,049 . The most active insiders traders include Capital Management, Lp Ferr..., Opportunities Fund (A) Lp A..., and Opportunities Fund (A) Lp A.... On average, Progenity executives and independent directors trade stock every 24 days with the average trade being worth of $1,994,758. The most recent stock trade was executed by Capital Management, Lp Ferr... on 14 June 2021, trading 8,097,166 units of PROG stock currently worth $20,000,000.



What does Progenity do?

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.



What does Progenity's logo look like?

Progenity, Inc. logo

Complete history of Mr Esparbes stock trades at Innoviva Inc and Progenity

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
20 May 2018 Eric D Esparbes
SVP and CFO
Sale 5,808 $14.40 $83,635
20 May 2018
373,081
20 Feb 2018 Eric D Esparbes
SVP and CFO
Sale 5,378 $16.52 $88,845
20 Feb 2018
291,810
20 Nov 2017 Eric D Esparbes
SVP and CFO
Sale 15,285 $13.28 $202,985
20 Nov 2017
321,742
20 Aug 2017 Eric D Esparbes
SVP and CFO
Sale 1,825 $12.20 $22,265
20 Aug 2017
343,168
20 May 2017 Eric D Esparbes
SVP and CFO
Sale 1,825 $11.85 $21,626
20 May 2017
350,763
20 Feb 2017 Eric D Esparbes
SVP and CFO
Sale 1,825 $12.07 $22,028
20 Feb 2017
354,296
20 Feb 2017 Eric D Esparbes
SVP and CFO
Sale 1,825 $12.07 $22,028
20 Feb 2017
354,296
20 Nov 2016 Eric D Esparbes
SVP and CFO
Sale 1,800 $10.89 $19,602
20 Nov 2016
231,327
20 Aug 2016 Eric D Esparbes
SVP and CFO
Sale 3,700 $11.77 $43,549
20 Aug 2016
236,193


Progenity executives and stock owners

Progenity executives and other stock owners filed with the SEC include: